Advertisement

Doripenem May Increase Mortality Risk in Ventilator-Associated Pneumonia — Physician’s First Watch

Medical News |
March 10, 2014

Doripenem May Increase Mortality Risk in Ventilator-Associated Pneumonia

By Kristin J. Kelley

The antibacterial doripenem (marketed as Doribax) may pose an increased risk for death in patients with ventilator-associated pneumonia, the FDA warned. The drug's label will be changed to reflect these risks.

In a 3-year trial that was ended early, patients taking a 7-day course of doripenem had increased mortality risk and lower clinical cure rates than those given a 10-day course of imipenem and cilastatin.

The revisions will also include a warning against unapproved use of doripenem for any type of pneumonia.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement